HRP20251457T1 - Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi - Google Patents

Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Info

Publication number
HRP20251457T1
HRP20251457T1 HRP20251457TT HRP20251457T HRP20251457T1 HR P20251457 T1 HRP20251457 T1 HR P20251457T1 HR P20251457T T HRP20251457T T HR P20251457TT HR P20251457 T HRP20251457 T HR P20251457T HR P20251457 T1 HRP20251457 T1 HR P20251457T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
use according
ruxolitinib
day
Prior art date
Application number
HRP20251457TT
Other languages
English (en)
Croatian (hr)
Inventor
Matthew Stubbs
Phillip C. Liu
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of HRP20251457T1 publication Critical patent/HRP20251457T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20251457TT 2020-06-03 2020-09-14 Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi HRP20251457T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034214P 2020-06-03 2020-06-03
EP20781202.5A EP4161528B1 (en) 2020-06-03 2020-09-14 Combination of ruxolitinib with incb057643 for use in the treatment of myeloproliferative neoplasms
PCT/US2020/050753 WO2021247064A1 (en) 2020-06-03 2020-09-14 Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
HRP20251457T1 true HRP20251457T1 (hr) 2026-01-02

Family

ID=72659928

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251457TT HRP20251457T1 (hr) 2020-06-03 2020-09-14 Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Country Status (23)

Country Link
EP (2) EP4161528B1 (https=)
JP (2) JP7669396B2 (https=)
KR (1) KR20230031242A (https=)
CN (1) CN115835868A (https=)
AU (1) AU2020451061A1 (https=)
CA (1) CA3184633A1 (https=)
CL (1) CL2022003409A1 (https=)
DK (1) DK4161528T3 (https=)
ES (1) ES3058891T3 (https=)
FI (1) FI4161528T3 (https=)
HR (1) HRP20251457T1 (https=)
IL (1) IL298200A (https=)
LT (1) LT4161528T (https=)
MA (1) MA59868B1 (https=)
MD (1) MD4161528T2 (https=)
MX (1) MX2022015220A (https=)
PH (1) PH12022553276A1 (https=)
PL (1) PL4161528T3 (https=)
PT (1) PT4161528T (https=)
RS (1) RS67440B1 (https=)
SI (1) SI4161528T1 (https=)
SM (1) SMT202600021T1 (https=)
WO (1) WO2021247064A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023009858A (es) * 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2024039883A2 (en) * 2022-08-19 2024-02-22 Translational Drug Development Llc Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms
AU2024306742A1 (en) * 2023-06-28 2025-12-04 Active Biotech Ab Quinoline carboxamides for use in the treatment of mpn

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제(R)―3―(4―(7H―피롤로[2,3-d]피리미딘―4―일)―1H―피라졸―1―일)―3―사이클로펜틸프로판니트릴의 염
PL3134403T3 (pl) * 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor

Also Published As

Publication number Publication date
IL298200A (en) 2023-01-01
LT4161528T (lt) 2026-02-10
SI4161528T1 (sl) 2026-01-30
EP4691563A2 (en) 2026-02-11
JP2023529365A (ja) 2023-07-10
PH12022553276A1 (en) 2024-02-19
EP4161528A1 (en) 2023-04-12
JP7669396B2 (ja) 2025-04-28
CN115835868A (zh) 2023-03-21
FI4161528T3 (fi) 2025-12-12
MX2022015220A (es) 2023-03-08
WO2021247064A1 (en) 2021-12-09
RS67440B1 (sr) 2025-12-31
DK4161528T3 (da) 2025-11-24
PT4161528T (pt) 2026-01-23
SMT202600021T1 (it) 2026-03-09
CL2022003409A1 (es) 2023-05-26
ES3058891T3 (en) 2026-03-13
AU2020451061A1 (en) 2022-12-15
CA3184633A1 (en) 2021-12-09
EP4691563A3 (en) 2026-04-01
KR20230031242A (ko) 2023-03-07
JP2025111539A (ja) 2025-07-30
MD4161528T2 (ro) 2026-03-31
PL4161528T3 (pl) 2026-03-16
MA59868B1 (fr) 2025-11-28
EP4161528B1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
HRP20251457T1 (hr) Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi
ES2818620T3 (es) Derivados de azabencimidazol como inhibidores de pi3k beta
ES2925698T3 (es) Compuestos heterocíclicos como inhibidores de la quinasa RET
ES2664794T3 (es) Inhibidores de ERK y métodos de uso
KR101680406B1 (ko) 특정 화학 물질, 조성물 및 방법
JP2010529209A5 (https=)
Buron et al. Recent advances in the chemistry and biology of pyridopyrimidines
AU2011367809B2 (en) Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
CN102264725B (zh) 蛋白激酶抑制剂
UY37925A (es) Formas cristalinas
CA3142340A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
SG187426A1 (en) Certain chemical entities, compositions and methods
TW200900404A (en) Pyrazolopyrimidine analogs and their use as mTOR kinase and PI3 kinase inhibitors
JP2016529292A5 (https=)
TW201105669A (en) Compounds and compositions as Syk kinase inhibitors
JP2020503271A (ja) 造血前駆体キナーゼ1(hpk1)阻害剤としてのアニリノピリミジンas
JP2014521725A5 (https=)
CN103717574A (zh) 用于抑制nampt的新化合物和组合物
HRP20170896T1 (hr) Derivati pirimidina
HRP20160370T1 (hr) Supstituirani 5-fluoro-1h-pirazolopiridini i njihova uporaba
WO2002055079A2 (en) Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
JP2020537672A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
KR20180070696A (ko) Mnk1 및 mnk2를 억제하는 피롤로-, 피라졸로-, 이미다조-피리미딘 및 피리딘 화합물
WO2024031089A1 (en) Sars-cov2 main protease inhibitors
CN107108632A (zh) 作为激酶调节剂的氘化的三唑并哒嗪